Preliminary results from an ongoing study suggest that those with a certain blood type may have some protection against the novel coronavirus.
In April, not long after the pandemic began, the genetic testing firm 23andMe began using its testing services to help scientists better understand how genetics may play a role in why some people who contract the novel coronavirus, SARS-CoV-2, develop severe infections, while others present only mild or moderate symptoms or have no symptoms at all.
On Monday, the company released early results from the study, which involved more than 750,000 participants.
“Preliminary data from 23andMe’s ongoing genetic study of COVID-19 appears to lend more evidence for the importance of a person’s blood type — determined by the ABO gene — in differences in the susceptibility to the virus,” the company said in a blog post regarding the findings.